October 8, 2012

NASDAQ OMX (NASDAQ: NDAQ) announces that the trading in Xvivo Perfusion AB (short name: XVIVO) shares will commence today on First North at NASDAQ OMX Stockholm. Xvivo Perfusion, which is a spin-off company from main market listed Vitrolife AB, belongs to the Healthcare sector and is the sixth new company to be admitted to trading on First North in 2012.

Xvivo Perfusion is a medical technology company focused on developing optimized solutions for organ and tissue preservation in connection with transplantation. The company delivers solutions and systems that can increase organ availability, improve the transplant process outcome and enhance the long-term outcomes and quality of life of the transplant recipient.

Read more about Xvivo Perfusion and follow the share here

See the interview with CEO Magnus Nilsson



Magnus Nilsson, CEO of Xvivo Perfusion is welcomed to First North by Emelie Jarnesten, NASDAQ OMX.



Magnus Nilsson, CEO and Fredrik Mattsson, Chairman of the board of Xvivo Perfusion are watching the first trades in the Xvivo share.



Fredrik Mattsson and Magnus Nilsson toll the bell to open the market.



Xvivo Perfusion together with their adviser, Redeye and NASDAQ OMX.